MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.

    N. Rocha, E. Furr-Stimming, A. Teixeira (Houston, TX, USA)

    Objective: To evaluate predictors for psychosis in HD. Background: Behavioral problems are present across all stages of HD, even preceding the development of the motor…
  • 2017 International Congress

    Examining central cognitive processing speed as an early marker of Huntington’s disease (HD) onset

    A. Nathan, S. Park, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

    Objective: To examine central processing speed as an early marker of Huntington’s disease (HD) onset using the Computerized Test of Information Processing (CTiP). Background: The CTiP,…
  • 2017 International Congress

    Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model

    N. Gonçalves, J. Mendes, J. Ferreira, C. Sampaio (Lisbon, Portugal)

    Objective: To develop a conceptual model to determine the rate of cognition impairment in Huntington's disease manifest patients and to identify the factors that influence…
  • 2017 International Congress

    Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation

    C. Fitzer-Attas, D. Stephenson, K. Romero, J. Neville, C. Sampaio (Critical Path Institute, Tucson, AZ; CHDI Foundation, Princeton, NJ)

    Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…
  • 2017 International Congress

    Salivary biomarkers for Huntington’s disease (HD)

    J. Corey-Bloom, A. Aikin, S. Park, A. Haque, A. Nathan, D. Granger, S. Granger, E. Thomas (La Jolla, CA, USA)

    Objective: The objective of the current study was to assess the potential for saliva to serve as a biospecimen for accessible biomarkers for Huntington’s disease…
  • 2017 International Congress

    The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

    S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

    Objective: To evaluate the safety and tolerability of deutetrabenazine in Huntington Disease (HD) over long term exposure. Background: In a randomized, double-blind, controlled trial (First-HD),…
  • 2017 International Congress

    The Huntington’s Disease Health Index Study (HD-HI)

    A. Glidden, E. Luebbe, M. Elson, S. Goldenthal, R. Dorsey, C. Heatwole (Rochester, NY, USA)

    Objective: To identify the symptomatic domains with the greatest impact on quality-of-life for those living with Huntington’s Disease (HD) through patient and caregiver interviews. Background:…
  • 2017 International Congress

    Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD)

    S. Park, S. Nam, A. Nathan, A. Haque, A. Haque, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

    Objective: To utilize the UCSD Huntington's Disease Behavioral Questionnaire (HD-BQ) to assess behavioral changes that distinguish HD gene carriers transitioning to manifest HD. Background: Behavioral…
  • 2017 International Congress

    Juvenile Huntington Disease (JHD) subjects’ stratification according to the mutation-length

    M. Marano, M. Marano, S. Migliore, S. Maffi, F. Consoli, A. Ciammola, E. Gatto, F. Squitieri (Rome, Italy)

    Objective: To identify clinical and genetic markers to differ JHD from adult Huntington disease (HD) and to monitor JHD progression Background: JHD is a HD…
  • 2017 International Congress

    Progressive microstructural abnormalities of the occipital cortex in Huntington’s disease

    O. Odish, R. Reijntjes, S. van_den Bogaard, R. Roos, A. Leemans (Leiden, Netherlands)

    Objective: To investigate the rate of longitudinal microstructural alterations in the occipital cortex in patients with different stages of Huntington’s disease (HD) compared to healthy…
  • « Previous Page
  • 1
  • …
  • 1238
  • 1239
  • 1240
  • 1241
  • 1242
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley